Infantile Spasms
Conditions
Keywords
Infantile spasms, vigabatrin, soluble tablets, acceptability, adherence, pharmacokinetics
Brief summary
The sponsor is developing a new paediatric formulation of vigabatrin to better adjust the dose to body weight and to limit waste of unused drug. The currently marketed vigabatrin (Sabril™) form only exists as 500 mg film coated tablets (for adults and children above 6 years) and 500 mg granules for oral solution sachets (for infants and children below 6 years). Sabril™ is not adapted for administration to infants when a fraction of the sachet is needed. Manual splitting of the sachet or lengthy and error-prone dilutions are often required. This study is a descriptive, non-randomized, open label multi-centric acceptability study in infants and children affected with infantile spasms. The primary objective is to describe the adherence to the new formulation. Secondary objectives include: * evaluation of the palatability and user-friendliness of the new treatment, * evaluation of the pharmacokinetic parameters of the new formulation, * PK parameters, * evaluation of the tolerance, * measurement of taurine plasma levels. This study will recruit up to 40 patients with infantile spasms and pharmacoresistant partial epilepsy aged 1 month to 6 years in 23 clinical sites in France.
Interventions
DRUGVigabatrin: Vigabatrin new ST formulation then Sabril®
* first treatment phase (V1/D1-V3/D84), in which patients already under Sabril® granules for oral solution and naive patients start the new ST formulation; patients already under Sabril® will start at the same dose and regimen as their usual Sabril®. Dose and regimen for naive patients will be chosen according to SPC. * second treatment phase (V3/D84-V4/D98) in which the patient is switched to Sabril® granules for oral solution (supplied by sponsor) for 15 days at the same dose as under the new ST formulation. Dose and treatment regimen should be maintained as in first treatment phase. \- At V4/D98, patients who received Sabril® granules for oral solution (supplied by sponsor) continue with marketed Sabril® treatment (or switches to another AED, according to the natural evolution of the patient's condition and upon investigator decision).
Sponsors
Institut National de la Santé Et de la Recherche Médicale, France
Hospices Civils de Lyon
National Research Agency, France
Orphelia Pharma
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
1 Months to 6 Years
Healthy volunteers
No
Inclusion criteria
* Patients with diagnosed infantile spasms (IS) or pharmacoresistant partial onset seizures (POS). * Infants \> 1 month and \< 6 months; infants \> 6 months and \< 2 years; and children \> 2 years and \< 6 years. * Patients under Sabril® or naive patients. * Patients under a twice-a-day posology of Sabril® or patients for whom vigabatrin will be given twice daily. Non inclusion Criteria: * Use of more than 2 other antiepileptic drugs as concomitant treatment (including steroids). Ketogenic diet can be in addition to these 2 other antiepileptic drugs. * Subjects receiving vigabatrin through a gastric tube. * Weight \< 1.750 Kgs. * Any planned major surgery within the duration of the trial. * Participation in any other clinical trial within 3 months prior to V1.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Individual adherence to the new Soluble Tablets (ST) formulation of Vigabatrin (VGB) using Medication Event Monitoring System (MEMS) | from V1 (day 1) to V3 (day 84), continuous assessment. | Adherence will be assessed by measurement of the dosing history of patients using an electronic Medication Event Monitoring System (MEMS).The date and time of each opening will be recorded |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| palatability of the new ST formulation and of Sabril® granules for oral solution. | during 7 consecutive days: from D90 to D96 under Sabril® and from D29 to D35 under the new ST formulation | Palatability of the treatment will be evaluated using a two face visual hedonic scale filled in by the parents and/or by the child, if feasible, on a daily basis. Each face of the scale will be assigned a score (1 to 2), and the average score will be calculated for the group. Palatability will be considered good if the average score for the group is at least 1.5 (out of a maximum of 2; Motte et al. 2005). |
| Ease of use of the new ST formulation and of Sabril® granules for oral solution. | during 7 consecutive days: from D90 to D96 under Sabril® and from D29 to D35 under the new ST formulation. | Ease of use will be evaluated using diaries filled by the parents or care-givers during 7 consecutive days: . Time required for preparation of both new ST formulation and Sabril® administrations will be averaged and compared, together with the global use satisfaction. |
| Adherence to the new ST formulation and to Sabril® granules for oral solution, by treatment unit accountability | VGB-ST: V1 (day 1) to V3 (day 84). Sabril®:V3 (day 85) to V4 (day 98) | Accountability of used and unused treatment units, retrieved by the patient at V3 and V4 |
| Safety and tolerance | Results of electroretinogram: when available from D1 to D126; Blood assessment: at D1 & D84; Vital signs at D1, D28, D84, D98 & D126; Adverse events, serious adverse events: evaluated for the duration of study participation (at D1, D28, D84, D98 & D126) | VGB safety profile is well known. The new ST formulation is expected to be bioequivalent to Sabril®, and since the new formulation does not contain excipients known to have a recognized action or effect at the dose used, the safety of the new formulation should be similar to that of Sabril®. Hence no other measures specific to the new ST formulation are included in the clinical acceptability study. |
| pharmacokinetic parameters for the new ST formulation (1 sample). Pharmacokinetic parameters for the new ST formulation (population PK) : Area under the curve (AUC), Tmax, Cmax, T½, Ka, V/F, Cl/F | PK D84: 1 sample before treatment. | The objective is to better characterize the developmental PK of vigabatrin during childhood. |
| Evaluation of the taurine plasma levels in children treated by vigabatrin. Taurine plasma concentration will be measured and a relationship between vigabatrin exposition and taurine plasma levels will be sought. | 1 sample will be drawn at V3 (day 84): just before treatment when patient is fasting. | — |
Countries
France
Outcome results
None listed